title: Osteopontin as a novel prognostic marker in stable ischaemic heart disease: a 3-year follow-up study.
abstract: OBJECTIVE
  Osteopontin (OPN) is a glycoprotein, which may play a major role in the regulation of biological phenomena. Increased levels of OPN have been linked to the presence and to the severity of atherosclerosis. This study was undertaken to assess the prognostic significance of plasma OPN levels in patients with stable ischaemic heart disease (IHD).
  
  
  METHODS
  In 101 patients with stable IHD and angiographically documented significant coronary artery stenosis, plasma OPN levels were measured at baseline (time of coronary arteriography). Patients were prospectively followed for a median time of 3 years (minimum 2.25, maximum 3.9 years). The primary study endpoint was the composite of cardiovascular death, non-fatal myocardial infarction, need for revascularization and hospitalization for cardiovascular reasons.
  
  
  RESULTS
  Baseline lnOPN levels were directly related to age (r = 0.27, P < 0.001) and inversely to left ventricular ejection fraction (r = -0.32, P < 0.01). Left ventricular ejection fraction was an independent predictor of plasma OPN levels after adjustment for age and gender (beta = -0.013, P = 0.02). Median OPN value was 55 ng mL(-1). In the univariate Cox-regression analysis, OPN levels > 55 ng mL(-1) (n = 50) were significantly related to adverse cardiac outcome (HR = 2.40, 95% CI: 1.11-5.23, P = 0.027). In multivariate model, OPN levels > 55 ng mL(-1) remained statistically significant independent predictor of adverse outcome after adjustment for age, gender, left ventricular ejection fraction and the number of diseased coronary arteries (HR = 2.88, 95% CI: 1.09-7.58, P = 0.032).
  
  
  CONCLUSIONS
  OPN may provide significant prognostic information independent of other traditional prognostic markers in patients with stable IHD.
authors.affiliation: Attikon University General Hospital, 1 Rimini Str., 12462 Athens, Greece. pg171@hlk.forthnet.gr
authors.forename: Panagiota
authors.initials: P
authors.lastname: Georgiadou
authors.forename: Efstathios K
authors.initials: EK
authors.lastname: Iliodromitis
authors.forename: Fotios
authors.initials: F
authors.lastname: Kolokathis
authors.forename: Christos
authors.initials: C
authors.lastname: Varounis
authors.forename: Vassilis
authors.initials: V
authors.lastname: Gizas
authors.forename: Manolis
authors.initials: M
authors.lastname: Mavroidis
authors.forename: Yassemi
authors.initials: Y
authors.lastname: Capetanaki
authors.forename: Harisios
authors.initials: H
authors.lastname: Boudoulas
authors.forename: Dimitrios T
authors.initials: DT
authors.lastname: Kremastinos
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000787:Angina Pectoris / Q000097:blood*; D015415:Biomarkers / Q000097:blood / Q000378:metabolism*; D023921:Coronary Stenosis / Q000097:blood*; D004812:Epidemiologic Methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D053495:Osteopontin / Q000097:blood* / Q000378:metabolism; D011379:Prognosis
chemical_list: D015415:Biomarkers; D053495:Osteopontin